Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05312736 · ClinicalTrials.gov registry record

Gyrate Atrophy Ocular and Systemic Study

A clinical trial of Gyrate Atrophy and Gyrata of Choroid and Retina; Atrophy, sponsored by Jaeb Center for Health Research.

Active
Registry status
46
Enrollment target
11
Study locations

NCT05312736: Active study of Gyrate Atrophy and Gyrata of Choroid and Retina; Atrophy, sponsored by Jaeb Center for Health Research.

NCT05312736 is a study of Gyrate Atrophy and Gyrata of Choroid and Retina; Atrophy that is active but no longer recruiting, run by Jaeb Center for Health Research. The registered enrollment target is 46 participants. The trial reports 11 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05312736, a study of Gyrate Atrophy and Gyrata of Choroid and Retina; Atrophy, is active but no longer recruiting, sponsored by Jaeb Center for Health Research.

ACTIVE NOT RECRUITING
Registry status
46 participants
Enrollment target
11
Study locations

Study Summary

The Gyrate Atrophy Ocular and Systemic Study characterizes the natural history of ornithine levels and retinal degeneration (RD) associated with disease-causing OAT variants in the presence of standard care dietary treatment regimens over 4 years. The research goal is to understand the impact of OAT mutations on plasma ornithine levels and retinal degeneration. Funding Source- FDA OOPD

Primary Outcome

Measured by Wide Field Fundus Autofluorescence (FAF)

Study Locations (11)

Other

  • Helsinki University Hospital - Helsinki
  • Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, INSERM-DGOS CIC1423 - Paris
  • University of Tuebingen, Centre for Ophthalmology - Tübingen
  • Vista Vision Eye Clinic - Brescia
  • Moorfields Eye Hospital - London

California

  • University of California San Francisco - San Francisco

Maryland

  • Johns Hopkins University, Wilmer Eye Institute - Baltimore

Massachusetts

  • Harvard Univ., Massachusetts Eye and Ear Infirmary - Boston

Pennsylvania

  • University of Pennsylvania - Philadelphia

Minas Gerais

  • INRET Clínica e Centro de Pesquisa - Belo Horizonte

Ontario

  • University of Toronto, Hospital for Sick Children - Toronto

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2023-11-21
Est. Completion 2028-12-31
Jaeb Center for Health Research

119 total trials

What the registry record for NCT05312736 still lists

NCT05312736 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 46 participants, a relatively small participant target.

The record links to 5 conditions, with Gyrate Atrophy appearing as the primary indexed condition, and to 0 interventions.

NCT05312736 lists 11 locations in 7 states (Other, California, Maryland).

Frequently Asked Questions

What is clinical trial NCT05312736 about?

NCT05312736 is a clinical study titled "Gyrate Atrophy Ocular and Systemic Study". The Gyrate Atrophy Ocular and Systemic Study characterizes the natural history of ornithine levels and retinal degeneration (RD) associated with disease-causing OAT variants in the presence of standard care dietary treatment regimens over 4 years. The research goal is to understand the impact of OAT...

What is the current status of trial NCT05312736?

This trial is currently active not recruiting. The enrollment target is 46 participants. The study started on 2023-11-21. Estimated completion is 2028-12-31.

What conditions does trial NCT05312736 study?

This clinical trial studies the following conditions: Gyrate Atrophy, Gyrata of Choroid and Retina; Atrophy, Ornithine-δ-aminotransferase, OAT, Chorioretinal Degeneration.

Who is sponsoring clinical trial NCT05312736?

This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05312736 being conducted?

This trial has 11 study locations across California, Maryland, Massachusetts, Pennsylvania, Minas Gerais. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01890590 · 46 participants · NA

    A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

  • NCT03191149 · 46 participants · Phase 2

    Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • NCT03510208 · 46 participants · Phase 1

    Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

  • NCT04048278 · 46 participants · Early Phase 1

    Lidocaine Infusion in Pancreatic Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05312736, the US trial registry maintained by the National Library of Medicine. NCT05312736 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.